

Modified Form PTO-1449

Atty. Docket
No. A-430F

Serial No.

NOT YET RECEIVED

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Bendele et al.Filing Date
July 17, 2001

Group

1646

S-
821/907263**U.S. PATENT DOCUMENTS**

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE APPROPRIATE
EA	A001	4,179,337	12/18/79	Davis et al.			
	A002	4,289,690	9/15/81	Pestka et al.			
	A003	4,766,106	8/23/88	Katre et al.			
	A004	4,847,325	7/11/89	Shadle et al.			
	A005	4,917,888	4/17/90	Katre et al.			
	A006	4,935,233	6/19/90	Bell et al.			
	A007	4,959,314	9/25/90	Mark et al.			
	A008	5,116,964	5/26/92	Capon et al.			
	A009	5,122,614	6/16/92	Zalipsky			
	A010	5,136,021	8/04/92	Dembinski et al.			
	A011	5,153,265	10/06/92	Shadle et al.			
	A012	5,166,322	11/24/92	Shaw et al.			
	A013	5,211,945	5/18/93	Wallach et al.			
	A014	5,252,714	10/12/93	Harris et al.			
	A015	5,359,037	10/25/94	Wallach et al.			
	A016	5,395,760	3/07/95	Smith et al.			
	A017	5,446,090	8/26/95	Harris			
	A018	5,478,925	12/26/95	Wallach et al.			
	A019	5,512,544	4/30/96	Wallach et al.			
	A020	5,605,690	2/25/97	Jacobs et al.			
	A021	5,610,279	3/11/97	Brockhaus et al.			
	A022	5,633,145	5/27/97	Feldmann et al.			
	A023	5,695,953	12/09/97	Wallach et al.			
	A024	5,712,155	1/27/98	Smith et al.			
↓	A025	5,739,208	4/14/98	Harris			

EXAMINER:

Eileen B.O. Harras

Date Considered:

12/26/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modified Form PTO-1449	Atty. Docket No. A-430F	Serial No. NOT YET RECEIVED
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	Applicant Bendele et al.	
	Filing Date July 17, 2001	Group 1646

U.S. PATENT DOCUMENTS

EXAMINER:

Eileen B. O'Hanrahan

Date Considered:

12/26/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modified Form PTO-1449		Atty. Docket No.	A-430F	Serial No.	NOT YET RECEIVED
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		Applicant	Bendele et al.		
		Filing Date	July 17, 2001		
		Group	1646		

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	TRANSLATION YES NO
EWA	B001	CA 2,003,743	5/23/90	Canada			
EWA	B002	DE 39 10 323 A1	10/19/89	Germany (see GB 2218101 A for English)			
	B003	EP 0 259 863 A2	3/16/88	Europe			
	B004	EP 0 308 378 A2	3/22/89	Europe			
	B005	EP 0 334 165 A2	9/27/89	Europe			
	B006	EP 0 393 438 A2	10/24/90	Europe (English Abstract attached)			
	B007	EP 0 398 327 A1	11/22/90	Europe			
	B008	EP 0 412 486 A1	2/13/91	Europe			
	B009	EP 0 417 563 A2	3/20/91	Europe (see U.S. 5,610,279 for English)			
	B010	EP 0 418 014 A1	3/20/91	Europe			
	B011	EP 0 422 339 A1	4/17/91	Europe			
	B012	EP 0 433 900 A1	6/26/91	Europe			
	B013	EP 0 512 528 A2	11/11/92	Europe			
	B014	EP 0 526 905 A2	2/10/93	Europe			
	B016	GB 2 218 101 A	11/08/89	Great Britain			
	B016	GB 2 246 569 A	2/05/92	Great Britain			
	B017	IL 90339	5/18/89	Israel			
	B018	WO 90/12874 A2	11/01/90	PCT			
	B019	WO 90/13575 A1	11/15/90	PCT (see U.S. 5,344,915 for English)			
	B020	WO 91/03553 A1	3/21/91	PCT			
	B021	WO 92/01002 A1	1/23/92	PCT (abstract attached)			
✓	B022	WO 92/01472 A1	2/06/92	PCT			

EXAMINER:	Eileen B.O. Nana	Date Considered:	12/26/02
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Modified Form PTO-1449	Atty. Docket No. A-430F	Serial No. NOT YET RECEIVED
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	Applicant Bendele et al.	
	Filing Date July 17, 2001	Group 1646

FOREIGN PATENT DOCUMENTS

EXAMINER: <i>Eileen B.O'Han</i>	Date Considered: <i>12/26/02</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Modified Form PTO-1449		Atty. Docket No. A-430F	Serial No. NOT YET RECEIVED
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Bendele et al.	
		Filing Date July 17, 2001	Group 1646

EXAMINER'S INITIALS	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
EPA	C001	Abuchowski et al., "Effect of Covalent Attachment of Polyethylene Glycol on Immunogenicity and Circulating Life of Bovine Liver Catalase", <i>Journal of Biological Chemistry</i> , 252(11):3582-3586 (1977).	
	C002	Aggarwal, et al., "Characterization of Receptors for Human Tumour Necrosis Factor and Their Regulation by γ -Interferon", <i>Nature</i> , 318:665-667 (1985).	
	C003	Akerblom et al., "Preparation and Characterization of Conjugates of Monoclonal Antibodies and Staphylococcal Enterotoxin A Using a New Hydrophilic Cross-Linker", <i>Bioconjugate Chem.</i> , 4:455-466 (1993).	
	C004	Ashkenazi et al., "Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin", <i>PNAS</i> 88: 10535-10539 (1991).	
	C005	Baglioni et al., "Binding of Human Tumor Necrosis Factor to High Affinity Receptors on HeLa and Lymphoblastoid Cells Sensitive to Growth Inhibition", <i>Journal of Biological Chemistry</i> , 260(25):13395-13397 (1985).	
	C006	Barrera P. et al., "Circulating Soluble Tumor Necrosis Factor Receptors, Interleukin-2 Receptors, Tumor Necrosis Factor Alpha, and Interleukin-6 Levels in Rheumatoid Arthritis. Longitudinal Evaluation During Methotrexate and Azathioprine Therapy.", <i>Arthritis & Rheumatism</i> , 36(8): 1070-1079 (1993)	
	C007	Bazzoni et al., "The Tumor Necrosis Factor Ligand and Receptor Families", <i>Seminars in Medicine of the Beth Israel Hospital, Boston</i> , 334(26):1717-1725 (1996).	
	C008	Beutler et al., "Passive Immunization against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin", <i>Science</i> , 229:869-871 (1985).	
	C009	Beutler and Cerami, "The Biology of Cachectin/TNF-A Primary Mediator of the Host Response", <i>Ann. Rev. Immunol.</i> , 7:625-655 (1989).	
	C010	Bologna, C. et al., "Association Des Traitements De Fond Dans La Polyarthrite Rheumatoïd", <i>Presse Medicale</i> , 25(19): 876-878 (1996)	
	C011	Borigini et al., "Combination Therapy", <i>Bailliere's Clinical Rheumatology</i> , 9(4):689-710 (1995).	
	C012	Brockhaus et al., "Identification of Two Types of Tumor Necrosis Factor Receptors on Human Cell Lines by Monoclonal Antibodies," <i>Proc. Natl. Acad. Sci. USA</i> , 87:3127-3131 (1990).	
	C013	Corcoran et al., "Characterization of Ligand Binding by the Human p55 Tumour-Necrosis-Factor Receptor Involvement of Individual Cysteine-Rich Repeats," <i>Eur. J. Biochem.</i> , 223: 831-840 (1994).	
	C014	Creasey et al., "A High Molecular Weight Component of the Human Tumor Necrosis Factor Receptor is Associated with Cytotoxicity," <i>Proc. Natl. Acad. Sci. USA</i> , 84:3293-3297 (1987).	
✓	C015	Davis et al., "Soluble, Nonantigenic Polyethylene Glycol-Bound Enzymes", <i>Biomedical Polymers: Polymeric Materials and Pharmaceuticals for Biomedical Use</i> , Goldberg et al. (Ed.). published by Academic Press (NY), pgs. 441-452 (1980).	

EXAMINER:	<i>Eileen B. O'Hara</i>	Date Considered:	<i>12/26/02</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Modified Form PTO-1449		Atty. Docket No. A-430F	Serial No. NOT YET RECEIVED
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Bendele et al.	
		Filing Date July 17, 2001	Group 1646

EXAMINER'S INITIALS	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
E.A	C016	Dayer et al., "Purification and Characterization of Human Tumor Necrosis Factor α Inhibitor," <i>Chemical Abstracts</i> , 113(38760n):454 (1990).	
	C017	Dayer et al., "Interleukin-1, Tumor Necrosis Factor and Their Specific Inhibitors," <i>European Cytokine Network</i> , 5(6):563-571 (1994).	
	C018	Elliott et al., "Randomised Double-blind Comparison of Chimeric Monoclonal Antibody to Tumour Necrosis Factor α (cA2) versus Placebo in Rheumatoid Arthritis" <i>Lancet</i> , 344:1105-1110 (1994)	
	C019	Engelmann et al., "A Tumor Necrosis Factor-Binding Protein Purified to Homogeneity from Human Urine Protects Cells from Tumor Necrosis Factor Toxicity," <i>J. Biol. Chem.</i> , 264(20):11974-11980 (1989).	
	C020	Engelmann et al., "Antibodies to a Soluble Form of a Tumor Necrosis Factor (TNF) Receptor Have TNF-Like Activity", <i>Journal of Biological Chemistry</i> , 265(24):14497-14504 (1990).	
	C021	Engelmann et al., "Two Tumor Necrosis Factor-Binding Proteins Purified From Human Urine," <i>J. Biol. Chem.</i> , 265(3):1531-1536 (1990).	
	C022	Feldman et al., "Receptor Activation by Antigens, Cytokines, Hormones, and Growth Factors" <i>Annals of The New York Academy of Sciences</i> , 766:272-278 (1995).	
	C023	Fisher et al., "Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein," <i>The New England Journal of Medicine</i> , 334(26): 1697-1702 (1996).	
	C024	Gatanaga et al., "Purification and Characterization of an Inhibitor (Soluble Tumor Necrosis Factor Receptor) for Tumor Necrosis Factor and Lymphotoxin Obtained from the Serum Ultrafiltrates of Human Cancer Patients," <i>Proc. National Academy of Science USA</i> 87:8781-8784 (1990).	
	C025	Goodwin et al., "Molecular Cloning and Expression of the Type 1 and Type 2 Murine Receptors for Tumor Necrosis Factor," <i>Molecular and Cell Biology</i> 11(6):3020-3026 (1991).	
	C026	Gray et al., "Cloning of Human Tumor Necrosis Factor (TNF) Receptor cDNA and Expression of Recombinant soluble TNF-Binding Protein," <i>Proc. Natl. Acad. Sci. USA</i> , 87(19):7380-7384 (1990).	
	C027	Hale et al., Cytokines and Their Receptors: From Clonal to Clinical Investigation -"Demonstration of <i>In Vitro</i> and <i>In Vivo</i> Efficacy of Two Biologically Active Human Soluble TNF Receptors Expressed in <i>E. Coli</i> ," <i>J. Cell. Biochem., Suppl.</i> 15F:113 (1991).	
	C028	Harris, Milton, "Laboratory Synthesis of Polyethylene Glycol Derivatives", <i>Rev. Macromol. Chem. Phys.</i> , 25(3):325-373 (1985).	
	C029	Harris et al., "Synthesis and Characterization of Poly(ethylene Glycol) Derivatives," <i>Journal of Polymer Science:Polymer Chemistry Edition</i> , 22:341-352 (1984).	
↓	C030	Hauser et al., "Cytokine Accumulations in CSF of Multiple Sclerosis Patients: Frequent Detection of Interleukin-1 and Tumor Necrosis Factor but not Interleukin-6," <i>Neurology</i> 40:1735-1739 (1990).	

EXAMINER: <i>Eileen B-O'Neal</i>	Date Considered: <i>12/26/02</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Modified Form PTO-1449		Atty. Docket No. A-430F	Serial No. NOT YET RECEIVED
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Bendele et al.	
		Filing Date July 17, 2001	Group 1646

EXAMINER'S INITIALS	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
EWA	C031	Heller et al., "Complementary DNA Cloning of a Receptor for Tumor Necrosis Factor and Demonstration of a Shed Form of the Receptor," <i>Proc. Natl. Acad. Sci. USA</i> , 87:6151-6155 (1990).	
	C032	Himmler et al., "Molecular Cloning & Expression of Human & Rat Tumor Necrosis Factor Receptor Chain (p60) and Its Soluble Derivative, Tumor Necrosis Factor-Binding Protein," <i>DNA and Cell Biology</i> , 9(10):705-715 (1990).	
	C033	Hofman et al., "Tumor Necrosis Factor Identified in Multiple Sclerosis Brain," <i>J. Exp. Med.</i> 170:607-612 (1989).	
	C034	Hohmann et al., "Two Different Cell Types Have Different Major Receptors for Human Necrosis Factor (TNF α)," <i>Journal of Biol. Chem.</i> 264: 14927-14934 (1989).	
	C035	Katz, <i>Am. J. Med.</i> , "Modern Management of Rheumatoid Arthritis", <i>The American Journal of Medicine</i> , 79 (suppl 4C):24-31 (1985).	
	C036	Kavanaugh et al., "Anti-TNG-Alpha Monoclonal Antibody (MAB) Treatment of Rheumatoid Arthritis (RA) Patients with Active Disease on Methotrexate (MTX); Results of a Double-Blind, Placebo Controlled Multicenter Trial", <i>Arthritis & Rheumatism</i> , 39(9):S123 (1996).	
	C037	Kohno et al., "A Second Tumor Necrosis Factor Receptor Gene Product Can Shed a Naturally Occurring Tumor Necrosis Factor Inhibitor," <i>Proc. Natl. Acad. Sci. USA</i> , 87:8331-8335 (1990).	
	C038	Krane and Simon, "Rheumatoid Arthritis: Clinical Features and Pathogenetic Mechanisms", <i>Advances in Rheumatology, Synderman (ed.)</i> , 70(2):263-284 (1986).	
	C039	Kull et al., "Cellular Receptor for 125 I-Labeled Tumor Necrosis Factor: Specific Binding, Affinity Labeling, and Relationship to Sensitivity," <i>Proc. Natl. Acad. Sci. USA</i> , 82:5756-5760 (1985).	
	C040	Lantz et al., "Characterization <i>In Vitro</i> of a Human Tumor Necrosis Factor-Binding Protein," <i>J. Clin. Invest.</i> , 86:1396-1402 (1990).	
	C041	Le et al., "Tumor Necrosis Factor and Interleukin 1: Cytokines with Multiple Overlapping Biological Activities," <i>Lab Investigation</i> 56(3):234-248 (1987).	
	C042	Lehmann et al., "Demonstration of Membrane Receptors for Human Natural and Recombinant 125 I-Labeled Tumor Necrosis Factor on HeLa Cell Clones and Their Role in Tumor Cell Sensitivity," <i>Eur. J. Biochem.</i> 158:1-5 (1986).	
	C043	Lindvall et al., "Modulation of the Constitutive Gene Expression of the 55 KD Tumor Necrosis Factor Receptor in Hematopoietic Cells," <i>Biochem. & Biophys. Res. Comm.</i> 172(2):557-563 (1990)	
✓	C044	Loetscher et al., "Molecular Cloning and Expression of the Human 55kd TNF Necrosis Factor Receptor," <i>Cell</i> , 61:351-359 (1990).	

EXAMINER:	Eileen B.O'Hara	Date Considered:	12/26/02
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Modified Form PTO-1449		Atty. Docket No. A-430F	Serial No. NOT YET RECEIVED
LIST OF REFERENCES CITED BY APPLICANT		Applicant Bendele et al.	
(Use several sheets if necessary)		Filing Date July 17, 2001	Group 1646

EXAMINER'S INITIALS	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
EAT	C045	Loetscher et al., "Recombinant 55-kDa Tumor Necrosis Factor (TNF) Receptor," <i>J. Biol. Chem.</i> 266(27):18324-18329 (1991).	
	C046	Marsters S. A. et al.: "Identification of Cysteine-Rich Domains of the Type 1 Tumor Necrosis Factor Receptor Involved in Ligand Binding", <i>The Journal of Biological Chemistry</i> , 267(9): 5747-5750 (1992).	
	C047	Moreland et al., "Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)-Fc Fusion Protein", <i>New England Journal of Medicine</i> , 337:141-147 (1997).	
	C048	Nophar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor," <i>The EMBO J.</i> , 9(10):3269-3278 (1990).	
	C049	Novick et al., "Soluble Cytokine Receptors are Present in Normal Human Urine," <i>J. Exp. Med.</i> 170:1409-1414 (1989).	
	C050	Novick et al., "Soluble Cytokine Receptors are Present in Normal Human Urine," <i>The Physiological and Pathological Effects of Cytokines</i> , pp. 413-421 (1990).	
	C051	Novick et al., "Purification of Soluble Cytokine Receptors from Normal Human Urine by Ligand-Affinity and Immunoaffinity Chromatography," <i>J. Chromatog.</i> 510:331-337 (1990).	
	C052	Olioff et al., "Tumors Secreting Human TNF/Cachectin Induce Cachexia In Mice", <i>Cell</i> , 50:555-563; (1987)	
	C053	Olsson et al., "Isolation and Characterization of a Tumor Necrosis Factor Binding Protein from Urine," <i>Eur. J. Haematology</i> , 42(3):270-275 (1989).	
	C054	Opal et al., "Potential Hazards of Combination Immunotherapy in the Treatment of Experimental Septic Shock", <i>The Journal of Infectious Diseases</i> , 173:1415-1421 (1996).	
	C055	Paleolog et al., "Deactivation Of Vascular Endothelium By Monoclonal Anti-Tumor Necrosis Factor α Antibody In Rheumatoid Arthritis," <i>Arthritis and Rheumatism</i> , 39:1082-1091 (1996)	
	C056	Peetre et al., "A Tumor Necrosis Factor Binding Protein is Present in Human Biological Fluids," <i>Eur. J. Haematology</i> , 41:414-419 (1988).	
	C057	Pennica et al., "Biochemical Properties of the 75-kDa Tumor Necrosis Factor Receptor", <i>Journal of Biological Chemistry</i> , 267(29):21172-21178 (1992).	
	C058	Peppel et al., "A Tumor Necrosis Factor (TNF) Receptor-IgG Heavy Chain Chimeric Protein as a Bivalent Antagonist of TNF Activity," <i>J. Exp. Med.</i> , 174:1483-1489 (1991).	
	C059	Rankin et al., "The Therapeutic Effects of an Engineered Human Anti-Tumour Necrosis Factor Alpha Antibody (CDP571) in Rheumatoid Arthritis", <i>British Journal of Rheumatology</i> , 34:334-342, (1995).	
	C060	Rhein, Reginald., "Another Sepsis Drug Down-Immunex' TNF Receptor," <i>Biotechnology Newswatch</i> , pgs. 1-3 (Monday, October 4, 1993).	
	C061	Schall et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor," <i>Cell</i> , 61:361-370 (1990).	
✓	C062	Scheurich et al., "Quantification and Characterization of High-Affinity Membrane Receptors for Tumor Necrosis Factor on Human Leukemic Cell Lines," <i>Int. J. Cancer</i> 38(1):127-133 (1986).	

EXAMINER:	<i>Eileen B.O'Hara</i>	Date Considered:	<i>12/26/02</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Modified Form PTO-1449		
Atty. Docket No. A-430F Serial No. NOT YET RECEIVED		
Applicant Bendele et al.		
Filing Date July 17, 2001 Group 1646		
(Use several sheets if necessary)		

EXAMINER'S INITIALS	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
CJA	C063	Seckinger et al., "A Human Inhibitor of Tumor Necrosis Factor Alpha," <i>J. Exp. Med.</i> , 167:1511-1516 (1988).
	C064	Seckinger et al., "A Urine Inhibitor of Interleukin 1 Activity Affects Both Interleukin 1 α and 1 β But Not Tumor Necrosis Factor α ," <i>J. Immunol.</i> 139(5):1541-1545 (1987).
	C065	Seckinger et al., "Characterization of a Tumor Necrosis Factor α (TNF- α) Inhibitor: Evidence of Immunological Cross-Reactivity with the TNF Receptor," <i>Proc. Natl. Acad. Sci. USA</i> , 87:5188-5192 (1990).
	C066	Seckinger et al., "Purification and Biologic Characterization of a Specific Tumor Necrosis Factor α Inhibitor," <i>J. Biol. Chem.</i> , 264(20):11966-11973 (1989).
	C067	Seckinger et al., "A Urine Inhibitor of Interleukin 1 Activity That Blocks Ligand Binding." <i>J Immunol.</i> , 139(5):1546-1549 (1987).
	C068	Seely et al., "Manufacturing of Recombinant Tumor Necrosis Factor Binding Protein 'Dumbbell' Using a 20K PEG BIS-Vinylsulfone Linker," 209 th Am. Chem. Soc. National Meeting; Anaheim, Cal., April 2-6, 1995, BIOT 68.
	C069	Seitz et al., "Methotrexate Action in Rheumatoid Arthritis: Stimulation of Cytokine Inhibitor and Inhibition of Chemokine Production by Peripheral Blood Mononuclear Cells", <i>British Journal of Rheumatology</i> , 34(7):602-609 (1995).
	C070	Seitz et al., "Interleukin 1 (IL-1) Receptor Antagonist, Soluble Tumor Necrosis Factor Receptors, IL-1 beta, and IL-8-markers of Remission in Rheumatoid Arthritis During Treatment with Methotrexate", <i>Journal of Rheumatology</i> , 23(9):1512-1516 (1996).
	C071	Selby et al. "Endogenous Tumour Necrosis Factor in Cancer Patients", <i>Lancet</i> , 1(8583):483 (1988).
	C072	Silberberg, "Diseases of Joints", Anderson's Pathology, Kissane (ed.), II:1828-1836 (1985).
	C073	Smith, Craig, "cDNA Expression: Cloning of the Receptor for Human Tumor Necrosis Factor." <i>Presentation Programme</i> , 29 th Midwinter Conference of Immunologists (January 27-30, 1990)
	C074	Smith, Craig, "cDNA Expression: Cloning of the Receptor for Human Tumor Necrosis Factor." <i>Presentation at the 29th Midwinter Conference of Immunologists</i> (January 27-30, 1990)
	C075	Smith et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins," <i>Science</i> , 248:1019-1023 (1990).
	C076	Smith et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins," <i>Genbank database excerpt released after publication</i> (May 1990)
↓	C077	Smith et al., "Species Specificity of Human and Murine Tumor Necrosis Factor," <i>J. Biol. Chem.</i> , 261(32):14871-14874 (1986).

EXAMINER:	<i>Eileen B-O'Hara</i>	Date Considered:	<i>12/26/02</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Modified Form PTO-1449		Atty. Docket No. A-430F	Serial No. NOT YET RECEIVED
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Bendele et al.	
		Filing Date July 17, 2001	Group 1646

EXAMINER'S INITIALS	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
GPA	C078	Spinas et al., "Induction of Plasma Inhibitors of Interleukin 1 and TNF-Alpha Activity by Endotoxin Administration to Normal Humans," <i>Am. J. Physiol.</i> 259:R993-R997 (1990).	
	C079	Starnes, Jr. et al., "Tumor Necrosis Factor and the Acute Metabolic Response to Tissue Injury in Man" 82:1321-1325 (1988).	
	C080	Stauber et al., "Human Tumor Necrosis Factor- α Receptor," <i>J. Biol. Chem.</i> , 263(35):19098-19104 (1988).	
	C081	Stauber et al., "Characterization and Affinity Cross-Linking of Receptors for Human Recombinant Lymphotoxin (Tumor Necrosis Factor- β) on a Human Histiocytic Lymphoma Cell Line U-937," <i>J. Biol. Chem.</i> 264(6):3573-3576 (1989).	
	C082	Tak et al., "Decrease in Cellularity and Expression of Adhesion Molecules by Anti-Tumor Necrosis Factor α Monoclonal Antibody Treatment in Patients with Rheumatoid Arthritis," <i>Arthritis and Rheumatism</i> , 39:1077-1081 (1996)	
	C083	Tracey et al., "Anti-Cachectin/TNF Monoclonal Antibodies Prevent Septic Shock During Lethal Bacteraemia," <i>Nature</i> 330:662-664 (1987).	
	C084	Tracey et al., "Metabolic Effects of Cachectin/Tumor Necrosis Factor Are Modified by Site of Production," <i>J. Clin. Invest.</i> 86:2014-2024 (1990).	
	C085	Tracey et al., "Physiological responses to cachectin," Tumor necrosis factor and related cytotoxins. Wiley, Chichester (Ciba Foundation Symposium 131), pp. 88-108 (1987).	
	C086	Tsujimoto et al., "Characterization and Affinity Crosslinking of Receptors for Tumor Necrosis Factor on Human Cells," <i>Archives of Biochem. & Biophys.</i> 249(2):563-568 (1986).	
	C087	Van Zee et al., "Tumor Necrosis Factor Soluble Receptors Circulate During Experimental and Clinical Inflammation and Can Protect Against Excessive Tumor Necrosis Factor α In Vitro and In Vivo", <i>Proc. Natl. Acad. Sci. USA</i> , 89:4845-4849 (1992).	
	C088	Vilcek et al., "Tumor Necrosis Factor: Receptor Binding and Mitogenic Action in Fibroblasts", <i>Journal of Cellular Physiology Supplement</i> 5:57-61 (1987).	
	C089	Vitt et al., "Biological and Structural Characterization of the Tumor Necrosis Factor Receptor on Multiple Cell Types: Relationship to Function", Fed. Proc. 78 th Annual Meeting of the American Society of Biological Chemists 46 (6):2117 (Abstract 1118) (1987)	
	C090	Waage et al., "Association Between Tumour Necrosis Factor in Serum and Fatal Outcome in Patients with Meningococcal Disease", <i>Lancet</i> , 1(8529):355 (1987)	
	C091	Wallach et al., "Cell Surface and Soluble TNF Receptors", Tumor Necrosis Factor: Structure-Function Relationship and Clinical Application, Osawa T; Bonavida B (eds), Karger, Basel. 47-57 (1992).	
✓	C092	Wallach et al., "Mechanisms Which Take Part in Regulation of the Response to Tumor Necrosis Factor," <i>Lymphokine Research</i> 8(3):359-363 (1989).	

EXAMINER:	Eileen B.O. Kara	Date Considered:	12/26/02
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Modified Form PTO-1449	Atty. Docket No. A-430F	Serial No. NOT YET RECEIVED
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	Applicant Bendele et al.	Filing Date July 17, 2001
		Group 1646

EXAMINER: <i>Cileen B. O'Hara</i>	Date Considered: 12/26/02
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Modified Form PTO-1449

Atty. Docket
No. A-430F

Serial No. 09/907,263


Applicant

Bendele et al.

Filing Date

July 17, 2001

Group



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
EN	A018	6,090,382	07/18/00	Salfeld et al.	/	1	
EN	A019	6,258,562	07/10/01	Salfeld et al.			RECEIVED
							OCT 08 2002

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	TRANSLATION YES NO
EN	B022	WO 97/29131	08/14/97	PCT	/	/	
EN	B023	WO 97/03686	02/06/97	PCT	/	/	
EN	B024	CA 2,227,136	02/06/97	Canada	/	/	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EN	C076	Yamamoto et al. (1996), "Effect of FR133605, a Novel Cytokine Suppressive Agent, on Bone and Cartilage Destruction in Adjuvant Arthritic Rats," <i>J. Rheumatol.</i> 23:1778-1783.

EXAMINER:

Eileen B. O'Hara

Date Considered:

12/26/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.